NEW YORK, Feb. 17 (GenomeWeb News) - Atugen has extended by one year its non-exclusive target validation and license agreement with Altana Pharma, the company said yesterday.

The extended deal, originally signed in 2001, calls for Atugen to continue validating potential targets supplied by Altana. The agreement provides a license to Altana's gene-silencing and oligonucleotide-delivery technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.